Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera ...

Denmark's Novo Nordisk, the maker of Ozempic and Wegovy obesity drugs, said on Wednesday it was lowering its 2025 outlook for the third time this year, after posting tepid third-quarter results.

Operating profit increased by 5% in Danish kroner and 10% at constant exchange rates (CER) to DKK 95.9 billion, impacted by one-off restructuring costs of around DKK 9 billion related to the ...

Intensifying competition, pricing pressure and copycat versions of Ozempic and Wegovy hold back sales at the pharma giant.

Eli Lilly and Novo Nordisk are expected to announce price reductions for their weight-loss drugs as part of the TrumpRx ...

Novo Nordisk, as well as Eli Lilly, would gain Medicare and Medicaid coverage for their blockbuster weight-loss drugs.

Eli Lilly and Novo Nordisk are expected to announce deals with the Trump administration to cut prices of their weight-loss ...

Obesity drugs have become an increasingly popular method of weight loss but most are not covered by insurance for that ...

Novo Nordisk’s latest offer is more than 30% above what Pfizer initially agreed to pay for the obesity biotech Metsera, not ...

Eli Lilly and Novo Nordisk are expected to announce deals with the Trump administration to cut prices of their weight-loss drugs in exchange for Medicare coverage, a White House source told Reuters on ...

Eli Lilly and Novo Nordisk are expected to announce deals with the White House to offer the lowest dose of their weight-loss ...

Eli Lilly and Novo Nordisk are expected to announce deals with the White House to offer the lowest dose of their weight-loss ...